Biology of proprotein convertase subtilisin kexin 9: Beyond low-density lipoprotein cholesterol lowering

QR Code

Biology of proprotein convertase subtilisin kexin 9: Beyond low-density lipoprotein cholesterol lowering

© 2016 The Author. Proprotein convertase subtilisin kexin 9 (PCSK9) is a key regulator of low-density lipoprotein receptor levels and LDL-cholesterol levels. Loss-of-function mutations in PCSK9 gene are associated with hypocholesterolaemia and protection against cardiovascular disease, identifying P...

Full description

Bibliographic Details
Main Authors:	Norata, Giuseppe, Tavori, H., Pirillo, A., Fazio, S., Catapano, A.
Format:	Journal Article
Published:	2016
Online Access:	http://hdl.handle.net/20.500.11937/55517

Similar Items

Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps
by: Baragetti, A., et al.
Published: (2018)

Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure-function relation to therapeutic inhibition
by: Tibolla, G., et al.
Published: (2011)

Treating high density lipoprotein cholesterol (HDL-C): Quantity versus quality
by: Pirillo, A., et al.
Published: (2013)

Vascular inflammation and low-density lipoproteins: Is cholesterol the link? A lesson from the clinical trials
by: Catapano, A., et al.
Published: (2017)

High-density lipoprotein subfractions - What the clinicians need to know
by: Pirillo, A., et al.
Published: (2013)

The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis
by: Pirillo, A., et al.
Published: (2018)

MicroRNAs and lipoproteins: A connection beyond atherosclerosis?
by: Norata, Giuseppe, et al.
Published: (2013)

Statins and periodontal inflammation: A pleiotropic effect of statins or a pleiotropic effect of LDL-cholesterol lowering?
by: Norata, Giuseppe, et al.
Published: (2014)

Emerging role of high density lipoproteins as a player in the immune system
by: Norata, Giuseppe, et al.
Published: (2012)

Targeting Cholesterol in Non-ischemic Heart Failure: A Role for LDLR Gene Therapy?
by: Catapano, A., et al.
Published: (2017)

The missing link between high-density lipoprotein cholesterol and inflammatory response in cardiovascular disease
by: Ammirati, E., et al.
Published: (2014)

High density lipoproteins and atherosclerosis: Emerging aspects
by: Sala, F., et al.
Published: (2012)

High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease
by: Baragetti, A., et al.
Published: (2013)

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: Patient selection and perspectives
by: Catapano, A., et al.
Published: (2017)

PCSK9 inhibition in statin-intolerant HeFH patients: What's new?
by: Casula, M., et al.
Published: (2017)

Targeting PCSK9 for hypercholesterolemia
by: Norata, Giuseppe, et al.
Published: (2014)

Postprandial lipemia as a cardiometabolic risk factor
by: Pirillo, A., et al.
Published: (2014)

Therapy and clinical trials: Aggressive statin therapy versus combined and emerging approaches
by: Catapano, A., et al.
Published: (2011)

Niemann-pick C1-like 1 (NPC1L1) inhibition and cardiovascular diseases
by: Pirillo, A., et al.
Published: (2016)

LOX-1, OxLDL, and atherosclerosis
by: Pirillo, A., et al.
Published: (2013)

HDLs, immunity, and atherosclerosis
by: Norata, Giuseppe, et al.
Published: (2011)

HDL in infectious diseases and sepsis
by: Pirillo, A., et al.
Published: (2015)

Strategies for the use of nonstatin therapies
by: Pirillo, A., et al.
Published: (2017)

PCSK9 inhibition for the treatment of hypercholesterolemia: Promises and emerging challenges
by: Norata, Giuseppe, et al.
Published: (2014)

New therapeutic principles in dyslipidaemia: Focus on LDL and Lp(a) lowering drugs
by: Norata, Giuseppe, et al.
Published: (2013)

Apolipoprotein C-III: From Pathophysiology to Pharmacology
by: Norata, Giuseppe, et al.
Published: (2015)

Versatility of subtilisin: a review on structure, characteristics, and applications
by: Mohd Azrin, Nur Aliyah, et al.
Published: (2022)

Does cigarette smoking exacerbate the effect of total cholesterol and high-density lipoprotein cholesterol on the risk of cardiovascular diseases?
by: Nakamura, K., et al.
Published: (2009)

HDL: To treat or not to treat?
by: Pirillo, A., et al.
Published: (2014)

HDL in innate and adaptive immunity
by: Catapano, A., et al.
Published: (2014)

Efficacy of Ganoderma lucidum on plasma lipids and lipoproteins in rats fed with high cholesterol diet
by: Tong, Chow Chin, et al.
Published: (2008)

Sibu olive inhibits artherosclerosis by cholesterol lowering effect in cholesterol fed-rabbit
by: M.H., Nurulhuda, et al.
Published: (2012)

Recent perspectives on the role of nutraceuticals as cholesterol-lowering agents
by: Ward, Natalie, et al.
Published: (2017)

PCSK9 inhibitors and dyslipidemia: The clinical evidence
by: Norata, Giuseppe
Published: (2014)

Heterozygous mthfr c677t polymorphism (rs1801133) is associated with higher total cholesterol/ high density lipoprotein cholesterol ratio in habitual coffee drinkers
by: Ong, Xuan
Published: (2023)

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
by: Yusuf, S., et al.
Published: (2016)

Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease
by: Yusuf, S., et al.
Published: (2016)

Factors associated with nonachievement of low density lipoprotein cholesterol target among patients with type 2 diabetes mellitus
by: Mat Yudin, Zainab
Published: (2015)

Leonurine: A new comer in the natural compounds affecting atherosclerosis
by: Norata, Giuseppe, et al.
Published: (2012)

HDL and adaptive immunity: A tale of lipid rafts
by: Norata, Giuseppe, et al.
Published: (2012)